Oncology Molecular Diagnostics Market 2024 - By Size, Share, Trends Analysis Report And Forecasts To 2033


Posted March 14, 2024 by Saitbrc

Global oncology molecular diagnostics market size is expected to reach $7.99 Bn by 2028 at a rate of 13.3%, segmented as by product, instruments, reagents, other products
 
The Oncology Molecular Diagnostics Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Oncology Molecular Diagnostics Market:
https://www.thebusinessresearchcompany.com/report/oncology-molecular-diagnostics-global-market-report

According to The Business Research Company’s Oncology Molecular Diagnostics Global Market Report 2024, The oncology molecular diagnostics market size has grown rapidly in recent years. It will grow from $4.19 billion in 2023 to $4.84 billion in 2024 at a compound annual growth rate (CAGR) of 15.6%. The growth in the historic period can be attributed to market entry of early tests, genomic profiling advancements, introduction of next-generation sequencing (ngs), early biomarker identification, targeted therapies development.

The oncology molecular diagnostics market size is expected to see rapid growth in the next few years. It will grow to $7.99 billion in 2028 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to advancements in liquid biopsy, rise of companion diagnostics, integration of artificial intelligence (ai), expansion of ngs applications, evolving biomarker identification. Major trends in the forecast period include global accessibility, biomarker discovery and validation, regulatory framework refinement, technological platform enhancements, patient-centric care models.

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the oncology molecular diagnostics market. According to the American Cancer Society, there were 1.8 million new cases and 0.6 million cancer deaths in 2021 in the USA. The four most common types of cancers worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the oncology molecular diagnostics market over the coming years.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=3457&type=smp

The oncology molecular diagnostics market covered in this report is segmented –
1) By Product: Instruments, Reagents, Other Products
2) By Technology: Polymerase Chain Reaction (PCR), In-situ Hybridization (ISH), Isothermic Nucleic Acid Amplification Technology (INNAT), Chips & Microarrays, Sequencing, Mass Spectroscopy, Transcription Mediated Amplification (TMA), Other Technologies
3) By End User: Hospitals, Diagnostic Centers, Academic & Research Institutes, Other End Users

Top Major Players
F. Hoffmann-La Roche AG
Bayer AG
Thermo Fisher Scientific Inc.
Abbott Laboratories
Danaher Corporation

The advanced technology in genomics is a key trend in the oncology molecular diagnostics market. Advancements in cancer genome sequencing technology, computational analysis, tumor models, and innovation of modern cancer research methods promote early detection of cancer and its mutation. For instance, in December 2021, Thermo Fisher Scientific Inc. a US-based company that manufactures oncology molecular diagnostics received FDA approval for an NGS-based companion diagnostic test that is used by non-small cell lung cancer patients. This test would assist medical professionals in deciding whether these patients would benefit from treatment with Janssen Biotech's targeted medication RYBREVANT (amivantamab-vmjw) .

The oncology molecular diagnostics market report table of contents includes:
1. Executive Summary
2. Oncology Molecular Diagnostics Market Characteristics
3. Oncology Molecular Diagnostics Market Trends And Strategies
4. Oncology Molecular Diagnostics Market - Macro Economic Scenario
5. Global Oncology Molecular Diagnostics Market Size and Growth
............................
32. Global Oncology Molecular Diagnostics Market Competitive Benchmarking
33. Global Oncology Molecular Diagnostics Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Oncology Molecular Diagnostics Market
35. Oncology Molecular Diagnostics Market Future Outlook and Potential Analysis
36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By TBRC
Country United States
Categories Health , Medical
Tags oncology molecular diagnostics market , oncology molecular diagnostics market share , oncology molecular diagnostics market size
Last Updated March 14, 2024